Risk factors for hypernatremia in patients with tolvaptan treatment

What is it about?

Tolvaptan is an orally active selective vasopressin V2 receptor antagonist that increases free-water clearance without electrolyte secretion. We aimed to determine the safety and risk factors associated with long-term tolvaptan treatment with regard to hypernatremia.

Featured Image

Why is it important?

The present study investigated the risk factors for hypernatremia with short- and long-term tolvaptan treatment. A low dose of tolvaptan is recommended to prevent hypernatremia, regardless of the treatment period. Elderly patients, especially those on long-term tolvaptan treatment, have a higher risk of hypernatremia.

Perspectives